Bortezomib plus low dose cytarabine in Int-2 and high risk MDS. Interim results of a phase I/II trial by the GFM

被引：0
|
作者：
Natarajan, Shahti [1 ]
Fenaux, Pierre [1 ]
Vey, Norbert [1 ]
Guerci, A. [1 ]
Coulibaly, I. [1 ]
Charbonnier, A. [1 ]
Ravoet, C. [1 ]
Courby, S. [1 ]
Etienne, G. [1 ]
Chaury, M. P. [1 ]
Cheze, S. [1 ]
Stamatoullas, A. [1 ]
Legros, L. [1 ]
Berger, E. [1 ]
Lescoute, A. [1 ]
Vaultier, S. [1 ]
Dreyfus, F. [1 ]
机构：
[1] Grp Francophone Myelodysplasies, Paris, France
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1453
引用
收藏
页码：435A / 435A
页数：1
相关论文
共 50 条
  • [31] Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial
    Ruhnke, Leo
    Schliemann, Christoph
    Mikesch, Jan-Henrik
    Stelljes, Matthias
    Fransecky, Lars
    Steffen, Bjoern
    Kaufmann, Martin
    Burchert, Andreas
    Rank, Andreas
    Hanoun, Maher
    Hoellein, Alexander
    Kraus, Sabrina
    Haenel, Mathias
    Schaefer-Eckart, Kerstin
    Haake, Annett
    Fiebig, Frank
    Zukunft, Sven
    Middeke, Jan Moritz
    Kunadt, Desiree
    Schetelig, Johannes
    von Bonin, Malte
    Roehnert, Maximilian Alexander
    Oelschlaegel, Uta
    Stoelzel, Friedrich
    Baldus, Claudia D.
    Serve, Hubert
    Wermke, Martin
    Bornhaeuser, Martin
    Roellig, Christoph
    BLOOD, 2023, 142
  • [32] ADVANCED PANCREATIC-CANCER - A PHASE I-II TRIAL OF CISPLATIN, HIGH-DOSE CYTARABINE, AND CAFFEINE
    DOUGHERTY, JB
    KELSEN, D
    KEMENY, N
    MAGILL, G
    BOTET, J
    NIEDZWIECKI, D
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (22) : 1735 - 1738
  • [33] High response rate to darbopoetin alfa in "low risk" MDS: Results of a phase II study.
    Mannone, L
    Gardin, C
    Quarre, MC
    Bernard, JF
    Giraudier, S
    Rosenthal, E
    Vassilief, D
    Hamza, F
    Park, S
    Kiladjian, JJ
    Vaultier, S
    Beyne-Rouzy, M
    Cheze, S
    Voilliat, L
    Agape, P
    Dreyfus, F
    Fenaux, P
    BLOOD, 2004, 104 (11) : 24A - 24A
  • [34] Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results
    Cortes, J. E.
    Feldman, E. J.
    Douer, D.
    Raza, A.
    Fruchtman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
    Roellig, Christoph
    Fransecky, Lars
    Hanoun, Maher
    Steffen, Bjorn
    Kraus, Sabrina
    Schliemann, Christoph
    Haake, Annett
    Fiebig, Frank
    Zukunft, Sven
    Alakel, Nael
    Middeke, Jan Moritz
    Bornhaeuser, Martin
    Stoelzel, Friedrich
    Schetelig, Johannes
    Ruhnke, Leo
    Kramer, Michael
    Von Bonin, Malte
    Roehnert, Maximilian Alexander
    Oelschlaegel, Uta
    Baldus, Claudia D.
    Serve, Hubert
    Wermke, Martin
    BLOOD, 2022, 140 : 3327 - 3328
  • [36] Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study
    Li, Yanyan
    Zhou, Haixia
    Wan, Chaoling
    Xu, Mingzhu
    Qian, Chongsheng
    Zhang, Tongtong
    Dai, Haiping
    Sun, AiNing
    Wu, Depei
    Xue, Shengli
    BLOOD, 2022, 140 : 3212 - 3213
  • [37] Study of oral clofarabine plus low-dose cytarabine in previously treated AML and high-risk MDS patients at least age 60
    Smith, K. M.
    Estey, E.
    Pagel, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
    Abdelall, Waleed
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Patel, Keyur P.
    Jabbour, Elias J.
    Daver, Naval G.
    Kadia, Tapan
    Gborogen, Rosilyn A.
    Konopleva, Marina
    Ravandi, Farhad
    Andreef, Michael
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [39] The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
    Swaminathan, Mahesh
    Kantarjian, Hagop M.
    Daver, Naval
    Borthakur, Gautam
    Ohanian, Maro
    Kadia, Tapan
    DiNardo, Courtney D.
    Jain, Nitin
    Estrov, Zeev
    Ferrajoli, Alessandra
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Andreeff, Michael
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Wierda, William G.
    Ravandi, Farhad
    Pinsoy, Maria Rhona
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [40] The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
    Borthakur, Gautam
    Kantarjian, Hagop M.
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Daver, Naval
    Kadia, Tapan M.
    Gborogen, Rosilyn
    Konopleva, Marina
    Andreeff, Michael
    Ravandi, Farhad
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
12345